Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
Adolescent
Adult
Aged
Antimalarials
/ administration & dosage
Cambodia
Child
Child, Preschool
Erythrocytes
/ cytology
Female
Genotype
Glucosephosphate Dehydrogenase
/ genetics
Hemoglobins
/ metabolism
Hemolysis
Humans
Malaria, Vivax
/ drug therapy
Male
Middle Aged
Primaquine
/ administration & dosage
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
07
04
2021
accepted:
28
07
2021
revised:
20
09
2021
pubmed:
9
9
2021
medline:
15
12
2021
entrez:
8
9
2021
Statut:
epublish
Résumé
Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery. Little is known how malaria affects glucose-6-phosphate dehydrogenase (G6PD) activity and whether changes in activity when patients present may lead qualitative tests, like the fluorescent spot test (FST), to misdiagnose G6PD deficient (G6PDd) patients as G6PD normal (G6PDn). Giving primaquine or tafenoquine to such patients could result in severe haemolysis. We investigated the G6PD genotype, G6PD enzyme activity over time and the baseline FST phenotype in Cambodians with acute P. vivax malaria treated with 3-day dihydroartemisinin piperaquine and weekly primaquine, 0·75 mg/kg x8 doses. Of 75 recruited patients (males 63), aged 5-63 years (median 24), 15 were G6PDd males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PDn; 6 patients had α/β-thalassaemia and 26 had HbE. Median (range) Day0 G6PD activities were 0·85 U/g Hb (0·10-1·36) and 11·4 U/g Hb (6·67-16·78) in G6PDd and G6PDn patients, respectively, rising significantly to 1·45 (0·36-5·54, p<0.01) and 12·0 (8·1-17·4, p = 0.04) U/g Hb on Day7, then falling to ~Day0 values by Day56. Day0 G6PD activity did not correlate (p = 0.28) with the Day0 reticulocyte counts but both correlated over time. The FST diagnosed correctly 17/18 G6PDd patients, misclassifying one heterozygous female as G6PDn. In Cambodia, acute P. vivax malaria did not elevate G6PD activities in our small sample of G6PDd patients to levels that would result in a false normal qualitative test. Low G6PDd enzyme activity at disease presentation increases upon parasite clearance, parallel to reticulocytosis. More work is needed in G6PDd heterozygous females to ascertain the effect of P. vivax on their G6PD activities. The trial was registered (ACTRN12613000003774) with the Australia New Zealand Clinical trials (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363399&isReview=true).
Sections du résumé
BACKGROUND
Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery. Little is known how malaria affects glucose-6-phosphate dehydrogenase (G6PD) activity and whether changes in activity when patients present may lead qualitative tests, like the fluorescent spot test (FST), to misdiagnose G6PD deficient (G6PDd) patients as G6PD normal (G6PDn). Giving primaquine or tafenoquine to such patients could result in severe haemolysis.
METHODS
We investigated the G6PD genotype, G6PD enzyme activity over time and the baseline FST phenotype in Cambodians with acute P. vivax malaria treated with 3-day dihydroartemisinin piperaquine and weekly primaquine, 0·75 mg/kg x8 doses.
RESULTS
Of 75 recruited patients (males 63), aged 5-63 years (median 24), 15 were G6PDd males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PDn; 6 patients had α/β-thalassaemia and 26 had HbE. Median (range) Day0 G6PD activities were 0·85 U/g Hb (0·10-1·36) and 11·4 U/g Hb (6·67-16·78) in G6PDd and G6PDn patients, respectively, rising significantly to 1·45 (0·36-5·54, p<0.01) and 12·0 (8·1-17·4, p = 0.04) U/g Hb on Day7, then falling to ~Day0 values by Day56. Day0 G6PD activity did not correlate (p = 0.28) with the Day0 reticulocyte counts but both correlated over time. The FST diagnosed correctly 17/18 G6PDd patients, misclassifying one heterozygous female as G6PDn.
CONCLUSIONS
In Cambodia, acute P. vivax malaria did not elevate G6PD activities in our small sample of G6PDd patients to levels that would result in a false normal qualitative test. Low G6PDd enzyme activity at disease presentation increases upon parasite clearance, parallel to reticulocytosis. More work is needed in G6PDd heterozygous females to ascertain the effect of P. vivax on their G6PD activities.
TRIAL REGISTRATION
The trial was registered (ACTRN12613000003774) with the Australia New Zealand Clinical trials (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363399&isReview=true).
Identifiants
pubmed: 34495956
doi: 10.1371/journal.pntd.0009690
pii: PNTD-D-21-00470
pmc: PMC8452019
doi:
Substances chimiques
Antimalarials
0
Hemoglobins
0
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Primaquine
MVR3634GX1
Banques de données
ANZCTR
['ACTRN12613000003774']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009690Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Med Genet. 1969 Mar;6(1):34-41
pubmed: 5771221
Am J Trop Med Hyg. 1998 May;58(5):645-9
pubmed: 9598455
J Lab Clin Med. 1954 Sep;44(3):439-42
pubmed: 13201853
Acta Haematol. 1965 Mar;33:129-38
pubmed: 14326932
Am J Trop Med Hyg. 2017 Sep;97(3):702-711
pubmed: 28749773
Clin Infect Dis. 2019 Sep 27;69(8):1440-1442
pubmed: 30753364
BMC Med. 2015 Aug 25;13:203
pubmed: 26303162
Q J Med. 1977 Jan;46(181):97-118
pubmed: 866571
Blood. 2012 Nov 15;120(20):4123-33
pubmed: 22993389
Malar J. 2018 Mar 2;17(1):101
pubmed: 29499733
Br J Haematol. 1969 Jun;16(6):537-49
pubmed: 5802491
PLoS One. 2014 Dec 26;9(12):e116143
pubmed: 25541721
Mediterr J Hematol Infect Dis. 2016 Aug 20;8(1):e2016038
pubmed: 27648201
Malar J. 2013 May 28;12:171
pubmed: 23714236
Bull World Health Organ. 1960;22:621-31
pubmed: 13793053
Ann Soc Belges Med Trop Parasitol Mycol. 1969;49(3):298-302
pubmed: 5351939
J Clin Invest. 1958 Nov;37(11):1542-8
pubmed: 13587663
PLoS Negl Trop Dis. 2016 Feb 19;10(2):e0004457
pubmed: 26894297
PLoS One. 2011;6(12):e28357
pubmed: 22164279
Transl Res. 2015 Jun;165(6):677-88
pubmed: 25312015
Lancet Infect Dis. 2019 Jan;19(1):10-12
pubmed: 30587279
Am J Trop Med Hyg. 2007 Oct;77(4):779-89
pubmed: 17978087
Lancet. 2019 Sep 14;394(10202):929-938
pubmed: 31327563
J Lab Clin Med. 1971 Feb;77(2):177-84
pubmed: 5540765
Elife. 2014 Nov 18;3:
pubmed: 25406065
Arch Intern Med. 1962 Feb;109:209-34
pubmed: 13919680
Malar J. 2019 Jan 23;18(1):20
pubmed: 30674319
Clin Chem. 1996 Dec;42(12):1930-7
pubmed: 8969628
Proc Natl Acad Sci U S A. 1978 Apr;75(4):1979-83
pubmed: 273924
PLoS One. 2016 Feb 05;11(2):e0148172
pubmed: 26849445
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Blood. 2020 Sep 10;136(11):1225-1240
pubmed: 32702756
Clin Infect Dis. 2001 Dec 15;33(12):1968-74
pubmed: 11700577
J Lab Clin Med. 1954 Aug;44(2):171-6
pubmed: 13184224
Blood. 1965 Jan;25:92-5
pubmed: 14255977